TENXClinical Trials•globenewswire•
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Sentiment:Neutral (55)
Summary
Enrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 6, 2025 by globenewswire